Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Aptalis Pharma Us Inc
WARNING LETTER
•Aptalis Pharma Us Inc•August 29, 2013

Aptalis Pharma Us Inc – FDA Warning Letter, Aug 29, 2013

Record Details

On August 21-22, 26, and 28-29, 2013, the FDA inspected Aptalis Pharma US, Inc., a specification developer of the Class II medical device "Flutter." The inspection found the device adulterated under 21 USC 351(h) because manufacturing, packing, storage, or installation methods, facilities, or controls did not conform to the Quality System regulation (21 CFR Part 820).

Violations included: 1. Failure of Medical Device Reporting (MDR) procedures to require documentation of all information evaluated for reportability (21 CFR 803.17(b)(1)). 2. Failure to justify not reporting device correction/removal actions to FDA, lacking required documentation (21 CFR 806.20(b)(4)). 3. Failure to establish adequate Corrective and Preventive Action (CAPA) procedures for analysis, investigation, verification/validation, and documentation of changes (21 CFR 820.100(a)). 4. Failure to adequately document CAPA activities and results, specifically regarding complaint records (21 CFR 820.100(b)). 5. Failure to establish and maintain adequate complaint handling procedures for all complaint types, including oral complaints, and evaluation for MDR reporting (21 CFR 820.198

Company
Aptalis Pharma Us Inc
Inspection date
August 29, 2013
Product type
Devices
Office
New Orleans District Office
People
  • David W. Mims
  • Andrew M. Stribling
  • Patricia K. Schafer
View Company Profile

ID · 0def7042-5cd0-43fd-a01e-3c87b45853b3

Violation Codes10
21 U.S.C. 321(h)21 U.S.C. 351(h)21 CFR 82021 CFR 803.17(b)(1)21 CFR 806.20(b)(4)21 CFR 820.100(a)21 CFR 820.100(b)21 CFR 820.198(a)21 CFR 820.198(a)(2)21 CFR 820.30(i)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aptalis Pharma Us Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.